CoChat
Cited by 160

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism

Eichinger, Sabine, Schönauer, Verena, Weltermann, Ansgar, Minar, Erich, Bialonczyk, Christine, Hirschl, Mirko, Schneider, Barbara, Quehenberger, Peter, Kyrle, Paul A. · 2004 · Blood

Abstract

The impact of fibrinolysis for predicting the risk for recurrent venous thromboembolism (VTE) is low. We prospectively followed up 600 patients with a first VTE and evaluated the thrombin-activatable fibrinolysis inhibitor (TAFI) as a risk factor for recurrence. A high TAFI level (75th or higher percentile in thrombosis patients) was associated with a 2-fold higher risk for recurrence compared with lower levels. The probability of recurrence 2 years after anticoagulation was 14.5% (95% confidence interval [CI], 8.6-20.4) among patients with high TAFI levels and 6.8% (95% CI, 4.3-9.3) among patients with lower levels (P = .006). Our data also support the concept of a linkage between fibrinolysis and the coagulation system. Patients with high TAFI levels had significantly higher levels of factors XI, VIII, and IX, and a high risk of recurrence was seen among patients with high TAFI levels and high levels of one of these factors. The relative risk (RR) for recurrence was highest among patients with high TAFI and high factor XI (RR, 2.9; 95% CI, 1.3-6.9), high factor VIII (RR, 6.5; 95% CI, 2.9-14.8), or high factor IX (RR, 2.0; 95% CI, 1.0-3.9) levels compared with patients with low levels of TAFI and one of these factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2003-10-3422

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 160

Metadata

Authors
Eichinger, S., Schönauer, V., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Schneider, B., Quehenberger, P., & Kyrle, P. A.
Venue
Blood
Published
2004-05-15
Volume
103
Issue
10
Pages
3773-3776
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2079175463
Cited by
160
References
2
FWCI
9.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. https://app.cochat.ai/papers/10.1182/blood-2003-10-3422
The paper
Eichinger, S., Schönauer, V., Weltermann, A., Minar, E., Bialonczyk, C., Hirschl, M., Schneider, B., Quehenberger, P., & Kyrle, P. A. (2004). Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. https://doi.org/10.1182/blood-2003-10-3422

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.